A novel biguanide-derivative promotes NEDD4-mediated FGFR1 ubiquitination through BMI1 to overcome osimertinib resistance in NSCLC
Objective: Osimertinib (OSI) therapy, a cornerstone in treating non-small cell lung cancer (NSCLC), has been severely limited by rapidly developing acquired resistance. Inhibition of bypass activation using a combination strategy holds promise in overcoming this resistance. Biguanides, with excellen...
Na minha lista:
| Principais autores: | , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
China Anti-Cancer Association
2025-11-01
|
| coleção: | Cancer Biology & Medicine |
| Assuntos: | |
| Acesso em linha: | https://www.cancerbiomed.org/content/22/11/1381 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|